From a neuron to a nation,
Alzheimer’s weaves a tangled trail.
What will it take to reach the end?
Alzheimer’s disease is pervasive.
Five million patients in the U.S. now, 14 million in 2050.
Alzheimer’s disease is expensive.
$226 billion now, $1 trillion in 2050
Alzheimer’s disease is profound.
It rearranges minds and lives. It changes the very meaning of the phrase “I love you.”
There is no proven prevention. There is no effective treatment. There is no cure.
There is not even a clear understanding of how it develops.
How does one make sense of this disease, the complexity of which is recapitulated and expanded at every level, from the snipping of a molecular protein to the posturing of politicians?
The road to prevent, to cure, or even to delay Alzheimer’s has been long and maddeningly frustrating. There is reason to hope, with four brand-new, highly powered, well-targeted drug trials aimed at preventing the buildup of amyloid plaque, thought by many to be the disease’s driving pathology. But only one of these trials has launched and all are years away from definitive answers.
The sobering truths are these: The underlying causes of Alzheimer’s disease remain largely unknown. There is almost certainly not just one precipitating pathology, but many. There is no consensus about where or when to interrupt these mechanisms – or even which one to target.
In the meantime, the disease ravages older people, especially women. According to the Alzheimer’s Association, a third of the elderly in this country die with Alzheimer’s or a related dementia. Of the 10 leading causes of death in the U.S., Alzheimer’s is the only one that cannot be prevented.
Diagnostic uncertainty and lack of patient disclosure are enormous issues. Only half of patients are informed about their suspected diagnosis, and even when they are, they may be suffering from a completely different dementia or disease.
There are no definitive methods of diagnosis. There is no blood test nor any other objective measure. Advances in biomarkers and imaging largely remain research tools; diagnosis largely remains clinical, based on subjective complaints and subjective tests. Thus, some patients go for several years with unhelpful, or even harmful, treatment.
These issues are the stepping stones we will follow here, with our own continuing journey. The Journey of a Thousand Steps will chronicle the journey to a satisfactory Alzheimer’s destination.
It will be a living record, updated with the latest research and clinical news.
It will be a political and social record, documenting both the government and grassroots struggles to cope with the disease’s impact.
Finally, and perhaps most importantly, it will be a personal record, documenting the hopes, the struggles, and the courage of families as they learn to live – and die – with Alzheimer’s.
We invite you to share the journey.
Walk with us.
Diagnosis and Therapy
Diagnosis and Therapy
From symptom management to cure
Where are researchers scoring therapeutic successes in ongoing trials?
The tangled path of amyloid and tau
What advances are needed to understand how Alzheimer’s disease progresses and to stop or even reverse it?
Moving from the known into the unknown
Alzheimer’s disease is a scientific puzzle. An economic disaster. A medical nightmare. But if we strip away all the big words and the big concepts, what remains is the struggle to hold on to personhood – and the struggle to let go.
Genes are seldom destiny
Emerging research suggests that preventing Alzheimer’s may be much more practical than treating it.
Costs And Coping
Costs And Coping
Caring and the caregivers
What is the future for supporting caregivers and how will the economy bear the brunt of increased costs?